Tanvex BioPharma Inc
Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that… Read more
Tanvex BioPharma Inc (6541) - Total Liabilities
Latest total liabilities as of September 2025: NT$2.17 Billion TWD
Based on the latest financial reports, Tanvex BioPharma Inc (6541) has total liabilities worth NT$2.17 Billion TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tanvex BioPharma Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Tanvex BioPharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tanvex BioPharma Inc Competitors by Total Liabilities
The table below lists competitors of Tanvex BioPharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Gicsa S.A. de C.V
MX:GICSAB
|
Mexico | MX$42.31 Billion |
|
Benchmark Bankshares Inc
PINK:BMBN
|
USA | $1.24 Billion |
|
Wireless Power Amplifier Module Inc
KQ:332570
|
Korea | ₩93.06 Billion |
|
Probi AB
ST:PROB
|
Sweden | Skr155.86 Million |
|
Sapura Energy Bhd
KLSE:5218
|
Malaysia | RM9.16 Billion |
|
B Communications Ltd
PINK:BCOMF
|
USA | $13.13 Billion |
|
Polight ASA
OL:PLT
|
Norway | Nkr33.56 Million |
|
vTv Therapeutics Inc
NASDAQ:VTVT
|
USA | $28.95 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Tanvex BioPharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tanvex BioPharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tanvex BioPharma Inc (2013–2024)
The table below shows the annual total liabilities of Tanvex BioPharma Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$1.84 Billion | -5.17% |
| 2023-12-31 | NT$1.94 Billion | -4.24% |
| 2022-12-31 | NT$2.03 Billion | +5.71% |
| 2021-12-31 | NT$1.92 Billion | +9.52% |
| 2020-12-31 | NT$1.75 Billion | +223.18% |
| 2019-12-31 | NT$542.12 Million | +105.41% |
| 2018-12-31 | NT$263.92 Million | +17.93% |
| 2017-12-31 | NT$223.78 Million | -25.22% |
| 2016-12-31 | NT$299.25 Million | +146.47% |
| 2015-12-31 | NT$121.41 Million | +86.52% |
| 2014-12-31 | NT$65.09 Million | -22.16% |
| 2013-12-31 | NT$83.63 Million | -- |